Targeting the untargeted: Molecular insights and emerging therapeutic strategies for primary aldosteronism

Area of Science:

• Endocrinology
• Molecular Medicine
• Cardiovascular Disease

Background:

• Primary aldosteronism (PA) is the leading cause of endocrine hypertension, increasingly recognized as a complex molecular syndrome.
• Somatic mutations contribute to PA pathogenesis, but the role of epigenetic dysregulation is a key area for research.
• Current treatments using conventional mineralocorticoid receptor antagonists (MCRAs) have limitations, including off-target effects and residual cardiovascular risk.

Purpose of the Study:

• To review the evolution of primary aldosteronism from a hormonal disorder to a molecular syndrome.
• To highlight the inadequacy of current management strategies and the need for personalized medicine.
• To synthesize evidence supporting molecular subtyping and next-generation therapies for PA.

Main Methods:

• Comprehensive literature synthesis of emerging evidence in PA.
• Critical appraisal of molecular mechanisms and therapeutic strategies.
• Analysis of the role of epigenetic dysregulation in PA pathogenesis.

Main Results:

• PA management is transitioning towards molecular subtyping.
• Next-generation agents like non-steroidal MCRAs and aldosterone synthase inhibitors (ASIs) offer targeted interventions.
• A paradigm shift is needed to address the dissociation between hypertension control and long-term organ protection.

Conclusions:

• Personalized medicine approaches are crucial for effective PA management.
• Molecular subtyping will enable tailored therapeutic strategies.
• Future research should focus on integrating molecular insights into clinical practice for improved patient outcomes.